# A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

> **NCT03569631** · PHASE2 · COMPLETED · sponsor: **Tetra Discovery Partners** · enrollment: 30 (actual)

## Conditions studied

- Fragile X Syndrome
- FXS
- Fra(X) Syndrome

## Interventions

- **DRUG:** BPN14770
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03569631
- **Lead sponsor:** Tetra Discovery Partners
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569631, "A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03569631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*